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Mitochondrial damage by α-synuclein causes
cell death in human dopaminergic neurons
Goutham K. Ganjam1,2,3, Kathrin Bolte4, Lina A. Matschke5, Sandra Neitemeier1, Amalia M. Dolga1,6,
Matthias Höllerhage 7, Günter U. Höglinger7, Agata Adamczyk8, Niels Decher5, Wolfgang H. Oertel2,3 and
Carsten Culmsee1,3,9
Abstract
Evolving concepts on Parkinson’s disease (PD) pathology suggest that α-synuclein (aSYN) promote dopaminergic
neuron dysfunction and death through accumulating in the mitochondria. However, the consequence of
mitochondrial aSYN localisation on mitochondrial structure and bioenergetic functions in neuronal cells are poorly
understood. Therefore, we investigated deleterious effects of mitochondria-targeted aSYN in differentiated human
dopaminergic neurons in comparison with wild-type (WT) aSYN overexpression and corresponding EGFP (enhanced
green ﬂuorescent protein)-expressing controls. Mitochondria-targeted aSYN enhanced mitochondrial reactive oxygen
species (ROS) formation, reduced ATP levels and showed severely disrupted structure and function of the dendritic
neural network, preceding neuronal death. Transmission electron microscopy illustrated distorted cristae and many
fragmented mitochondria in response to WT-aSYN overexpression, and a complete loss of cristae structure and
massively swollen mitochondria in neurons expressing mitochondria-targeted aSYN. Further, the analysis of
mitochondrial bioenergetics in differentiated dopaminergic neurons, expressing WT or mitochondria-targeted aSYN,
elicited a pronounced impairment of mitochondrial respiration. In a pharmacological compound screening, we found
that the pan-caspase inhibitors QVD and zVAD-FMK, and a speciﬁc caspase-1 inhibitor signiﬁcantly prevented aSYN-
induced cell death. In addition, the caspase inhibitor QVD preserved mitochondrial function and neuronal network
activity in the human dopaminergic neurons overexpressing aSYN. Overall, our ﬁndings indicated therapeutic effects
by caspase-1 inhibition despite aSYN-mediated alterations in mitochondrial morphology and function.
Introduction
Parkinson’s disease (PD) is a neurodegenerative move-
ment disorder characterised by the progressive dopami-
nergic neurodegeneration in the substantia nigra pars
compacta. Aggregation of aSYN into Lewy bodies (LBs) is
a hallmark of PD, dementia with LBs, and neurodegen-
erative synucleinopathies like multiple systems atrophy or
pure autonomic failure1. Duplication, triplication or
A30P, A53T, A53E, G51D, or E46K point mutations in
the aSYN gene have been associated with autosomal-
dominant forms of PD2,3. Transgenic animal models of
PD and cellular overexpressing aSYN revealed mito-
chondrial localisation of aSYN may accelerate aSYN
toxicity in dopaminergic neurons4–6. Familial forms of
PD-like mutations in PTEN-induced putative kinase-1,
aSYN, leucine-rich repeat kinase-2, parkin or DJ-1 have
also been associated with dysfunctional mitochondria7,8.
Variety of cell death mechanisms were linked to the
pathogenesis of PD, such as extrinsic and intrinsic apop-
tosis, (regulated) necrosis and autophagy9. Studies in
Lund human mesencephalic (LUHMES) neurons identi-
ﬁed an iron-dependent ferroptosis cell death pathway is
involved in the pathogenesis of PD10. In programmed cell
death (PCD), impaired redox balance, deregulated cellular
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homeostasis and death signalling pathways converge at
the mitochondria. Dysfunctional mitochondria undergo
fragmentation and loss of membrane potential, and
enhanced reactive oxygen species (ROS) levels promoting
neurodegeneration11. Oxidative conditions results in
phosphorylation at serine 129 of aSYN, thereby initiating
the formation of toxic insoluble aSYN oligomers12. aSYN
neurotoxicity shares molecular events observed in PCD,
including mitochondrial dysfunction, failure of autophagy,
impaired redox balance and calcium deregulation13–15.
A fraction of aSYN associated with mitochondria or
supraphysiological levels of aSYN interacts with endo-
plasmic reticulum and mitochondrial complex I impairing
mitochondrial function4,16–18. Interactions of aSYN with
mitochondria were identiﬁed in the mitochondrial frac-
tions from the SN of PD4. A speciﬁc transcript of aSYN
containing a long 3′-untranslated region (UTR) that was
identiﬁed in PD patient’s brain tissue showed preferential
accumulation of aSYN in the mitochondria19. These
observations strongly suggest the existence of a mito-
chondrial variant of aSYN that may signiﬁcantly con-
tribute to dopaminergic neurodegeneration. However,
studies on aSYN variants directly targeting mitochondria
to investigate the dopaminergic neurodegeneration are
not reported. Therefore, this study focused on the over-
expression of a mitochondria-targeted aSYN and its
implications on mitochondrial function and cell viability
in LUHMES cells. Differentiated LUHMES dopaminergic
neurons provide a validated in vitro model system to
investigate the neurodegenerative mechanisms associated
with aSYN toxicity20. By using LUHMES system, we
investigated the deleterious effects of mitochondrial aSYN
localisation with a particular focus on mitochondrial
ultrastructure and respiratory function. Furthermore, we
screened different compound classes for inhibition of
aSYN-mediated mitochondrial damage and neurotoxicity.
Our ﬁndings indicated that caspase activation occurs
upstream of mitochondrial pathways of aSYN toxicity.
Materials and methods
Chemical compounds
The chemical inhibitors used to test against aSYN
toxicity in this study are listed here. QVD-OPh (N-(2-
quinolyl)valyl-aspartyl-(2,6-diﬂuorophenoxy)methylk-
etone) (EMD-Millipore, Billerica, MA, USA) and zVAD-
FMK (N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) ﬂuor-
omethyl ketone (Enzo Life Sciences, Farmingdale, NY,
USA) are broad-spectrum caspase inhibitors. For con-
venience from here on QVD-OPh is referred to as QVD.
DHB (ethyle-3,4-dihydroxybenzoate) (Sigma-Aldrich,
St. Louis MO, USA) is a HIF-PHDs (hypoxia-inducible
factor prolyl hydroxylases) inhibitor. NS309 (Sigma-
Aldrich, St. Louis MO, USA) is a SK channel activator and
interleukin-1β-converting enzyme (ICE-1) inhibitor II or
caspase-1 inhibitor, YVAD-CMK (ICE-1 is also known as
caspase-1) (EMD-Millipore, Billerica, MA, USA). All the
inhibitors used in this study were dissolved in dimethyl
sulfoxide (DMSO) and treated LUHMES cells at a con-
centration of 10 µM after 24 h of AAV (adeno-associated
viral vector) viral infections and DMSO was used as
vehicle control. After 48 h of the drug treatment, the cells
were subjected to respective analysis.
Recombinant AAV2-aSYN viral vector engineering and
virus generation
The human complementary DNA (cDNA) for WT-aSYN
from pcDNA3 aSYN was excised by Nhe1 and HindIII
restriction enzymes (Thermo Fisher Scientiﬁc, Darmstadt,
Germany) and subcloned into AAV2-hSynapsin-EGFP-
WPRE vector by replacing the EGFP (enhanced green
ﬂuorescent protein) reporter gene to obtain AAV2-
hSynapsin-aSYN-WPRE21,22. For mitochondrial-speciﬁc
overexpression of aSYN, we ligated the mitochondrial
localisation sequence (MLS) of cytochrome c encoding
nearly 3 kDa at the 5′ of aSYN cDNA to obtain AAV2-
hSynapsin-mito-aSYN-WPRE. Similarly, MLS was cloned
in front of EGFP to obtain AAV2-hSynapsin-mito-EGFP-
WPRE vector for mitochondrial EGFP control vector. All
the AAV2 viral vectors applied in this study use the human
synapsin promoter to restrict the transgene expression only
to neurons. The presence of a Woodchuck hepatitis virus
post-transcriptional regulatory element (WPRE) enhances
the stability of the messenger RNA (mRNA) and sustained
transgene expression. All molecular cloning procedures
were performed in SURE2 bacterial cells to minimise
unwanted recombinant events. Recombinant AAV vectors
of serotype 2 were produced by transfecting AAV cis
plasmids encoding the gene of interest and a viral helper
plasmid pDG2 as previously described23. The obtained
AAV viruses are referred to as AAV2/2, where the ﬁrst
number determines the genotype and the second number
indicates the serotype. The titre of the viruses was mea-
sured by quantifying the isolated viral genome by using
quantitative PCR. For convenience reasons, the cytosolic
vectors were named AAV2-hSyn-EGFP or AAV2-hSyn-
aSYN and mitochondrial AAV vectors were named AAV2-
hSyn-mito-EGFP or AAV2-hSyn-mito-aSYN throughout
the paper.
LUHMES and primary rat cortical neuronal cell culture
Post-mitotic differentiated human dopaminergic neu-
ronal cells LUHMES were used in this study24,25.
LUHMES cells were proliferated in cell culture ﬂasks
(Nunclon DELTA surface, NUNC A/S, St. Louis, MO,
USA) coated with 0.1 mg/ml poly-L-lysine (PLL) (Sigma-
Aldrich, St. Louis MO, USA) at +4 °C overnight. For
experiments, cell culture dishes were coated with 0.1mg/ml
PLL overnight and washed three times with sterile water,
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followed by coating with 5 µg/ml ﬁbronectin (Sigma-
Aldrich, St. Louis MO, USA) overnight in the incubator
(37 °C, 5% CO2). Before plating the cells, ﬁbronectin was
removed, and the wells were washed with phosphate-
buffered saline (PBS) and dried. Cells were plated at a
density of 55,000/cm2 in Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/F12 (Sigma-Aldrich, St. Louis MO,
USA) with 1% N2-supplement (Life Technologies, Carls-
bad, CA, USA), 0.04 µg/ml basic ﬁbroblast growth factor
(R&D Systems, Minneapolis, MN, USA). After 24 h of
plating, the medium was exchanged to differentiation
medium DMEM/F12 with 1% N2-supplement, 1 µg/ml
tetracycline, 0.49 mg/ml dibutyryl cyclic AMP (Sigma-
Aldrich, St. Louis MO, USA) and 2 ng/ml glial cell-
derived neurotrophic factor (R&D Systems, Minneapolis,
MN, USA)26. Following 5 days of differentiation, the cells
were replenished with fresh media and infected with
AAV2 viral particles at a concentration of 1012 genomic
copies per millilitre (gc/ml). After 72 h, the cells were
washed once with 1× PBS and subjected to the respective
analysis. Primary rat cortical neurons were isolated from
embryonic day 18 (E18) Sprague–Dawley rats and cul-
tured as explained27. Two-day cultured primary cortical
neurons were replenished with fresh media and infected
with AAV2 viral particles at a concentration of 1012 gc/ml.
After 72 h, the cells were washed with 1× PBS and used
for the respective analysis.
Protein extraction and Western blotting
For protein analysis, cells were brieﬂy washed with 1×
PBS and lysed with a buffer containing 0.25M mannitol,
0.05M Tris, 1 M EDTA (ethylenediaminetetraacetic acid),
1M EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,
N′,N′-tetraacetic acid), 1 mM DTT (dithiothreitol), 1%
Triton X (Sigma-Aldrich, St. Louis MO, USA), and sup-
plemented with complete mini protease and phosphatase
inhibitor cocktail tablets (Roche Diagnostics, Mannheim,
Germany). Cell membrane fragments and other insoluble
components from the lysates were pelleted by cen-
trifugation at 13,000 × g for 10 min at 4 °C. Total protein
amount was determined by using the Pierce BCA protein
assay kit (Thermo Fisher Scientiﬁc, Darmstadt, Germany)
and 30 µg of protein samples were run on a 12.5% sodium
dodecyl sulfate gel and subsequently blotted onto a PVDF
(polyvinylidene ﬂuoride) membrane at 15 V for 90min.
The membranes were incubated overnight with primary
rabbit anti-aSYN antibodies 1:1000 (Santa Cruz, SC-7011-
R, clone-20, now discontinued) or mouse monoclonal
anti-aSYN antibodies 1:1000 (Santa Cruz, SC-12767,
clone-211) or 1:10,000 mouse monoclonal anti-actin
antibodies (mpbio, MP-691001, clone-4) or goat anti-
EGFP antibodies 1:1000 (Rockland Immunochemicals,
600-101-215M) at 4 °C. After incubation with the corre-
sponding secondary horse radish peroxidase (HRP)-
labelled antibody (Vector Laboratories, Burlingame, CA,
USA) and HRP substrate (PJK GmbH, Kleinblittersdorf,
Germany), chemiluminescence was detected with Che-
midoc software (Bio-Rad, Munich, Germany).
Immunocytochemistry
Differentiated human dopaminergic neurons were ﬁxed
by using 4% paraformaldehyde for 15 min and permea-
bilised by Triton X-100 at 0.04% as described before28.
Primary antibodies against human aSYN (Santa Cruz C20;
Santa Cruz Biotechnology, Dallas, USA), β3-tubulin
(Invitrogen, Karlsruhe, Germany) at a concentration of
1:200 were incubated overnight at 4 °C, followed by sec-
ondary anti-rabbit, anti-mouse antibodies coupled to
ﬂuorophore Dyelight 488, and Dyelight 649 (Invitrogen)
at a concentration of 1:500. Images were obtained by
using a CCD camera (DFC 360, FX, Leica, Wetzlar,
Germany) connected to an epiﬂuorescent microscope
(DMI 6000 B, Leica). For co-localisation studies, cells
were co-stained with MitoTracker Deep Red (200 ng/ml)
for mitochondria and DAPI (4′,6-diamidino-2-pheny-
lindole, 1 µg/ml) for the nucleus. Quantiﬁcation and
analysis of neuronal network was performed by using the
Image J software.
Cell viability
Cell viability was quantiﬁed by the reduction of MTT
(3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide) by the LUHMES cells for 1 h in the cell cul-
ture incubator. Total medium containing MTT was
removed, and the cell culture dishes were frozen at
−80 °C for at least an hour to stop the reaction. After
thawing at room temperature, the dye was dissolved in
80 µl of DMSO, and the absorbance was measured at
570 nm with a reference ﬁlter at 630 nm with a FLUOStar
OPTIMA reader (BMG Labtech, Ortenberg, Germany) as
described29.
Additionally, to analyse the cell viability at different time
intervals, we also measured the lactate dehydrogenase
(LDH) release in the media after 24, 48, and 72 h of viral
infections by using commercially available LDH-GloTM
Cytotoxicity assay (J2380).
ATP measurement
ATP levels in human dopaminergic neurons upon aSYN
overexpression were analysed by luminescence detection
according to the manufacturer’s protocol from ViaLight
TM plus kit (Lonza, Verviers, Belgium). LUHMES cells
were cultured and differentiated on white 96-well plates
(10,000 cells/well, Greiner Bio-one, Frickenhausen, Ger-
many). After 72 h of aSYN expression, ATP levels
were analysed by luminescence detection using a
FLUOstar OPTIMA reader (BMG Labtech, Offenburg,
Germany).
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Mitochondrial membrane potential analysis
Changes in the mitochondrial membrane potential in
human dopaminergic neurons upon aSYN-induced toxi-
city were analysed by staining the cells with TMRE (tet-
ramethylrhodamine ethyl ester) dye (Invitrogen,
Karlsruhe, Germany). Cells were cultured and differ-
entiated on PLL/ﬁbronectin-coated coverslips in 24-well
plates and infected with respective AAV viruses. After
72 h, cells were incubated with culture medium contain-
ing 200 nM TMRE dye for 30 min at 37 °C. Cells were
washed brieﬂy with PBS and imaged immediately with an
epiﬂuorescence microscope at an excitation wavelength of
620 and 670 nm for emission (red). Cells harbouring red
ﬂuorescing mitochondria were considered healthy and
quantiﬁed from at least 500 cells per condition from three
independent experiments without the knowledge of
treatment history, and the control in each individual
experiment was set as 100%.
Mitochondrial ROS analysis
Generation of mitochondrial ROS in response to aSYN
toxicity was analysed by staining the LUHMES cells with
MitoSOX Red (Invitrogen, Karlsruhe, Germany).
LUHMES cells cultured on PLL/ﬁbronectin-coated cov-
erslips in 24-well plates were infected with respective
AAV2 viruses for 48 h. Cells were incubated with medium
containing 200 nM MitoSOX red for 30min at 37 °C.
Then, the cells were gently washed with PBS and imaged
immediately using an epiﬂuorescence microscope at a
wavelength of 620 nm excitation and 670 nm emission
(red). Quantiﬁcation of ROS producing, that is, red
ﬂuorescing mitochondria from at least 500 cells per
condition was performed from three independent
experiments without the knowledge of the treatment
history, and the control in each individual experiment was
set as 100%.
Electrophysiology
Electrical activity of human dopaminergic neurons was
measured by on-cell and whole-cell patch-clamp record-
ings using an Axopatch 200B ampliﬁer (Molecular Devi-
ces, Sunnyvale, CA, USA) and Clampex 10.0 software
(Molecular Devices, Sunnyvale CA, USA). Patch pipettes
were prepared from borosilicate glass capillaries GB
150TF-8P (Science Products, Hofheim, Germany), and
had tip resistances between 3 and 5MΩ. Cells were
continuously superfused with an extracellular solution
consisting of (in mM): 138 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6
CaCl2, 25 D-glucose, and 5 HEPES (pH 7.4 adjusted with
NaOH). Whole-cell patch-clamp experiments were con-
ducted with an internal solution containing (in mM): 10
NaCl, 76 K2SO4, 10 KCl, 1 MgCl2, and 5 HEPES (pH 7.35
with KOH). Recordings of spontaneous action potentials
were obtained in the on-cell voltage clamp conﬁguration,
and membrane potential recordings were performed in
the whole-cell current clamp conﬁguration. Data were
digitised at 10 kHz with a Digidata 1440A digitiser
(Molecular Devices, Sunnyvale CA, USA) and ﬁltered at
1–5 kHz. Electrode capacitance was compensated, and
only cells with series resistances lower than 15MΩ were
recorded. Data were analysed with ClampFit10 (Mole-
cular Devices, Sunnyvale, CA, USA).
Oxygen consumption rate determination
Changes in mitochondrial respiration function of
human dopaminergic neurons upon aSYN expression
were analysed using the XFe96 analyser from Seahorse
Bioscience (Agilent Technologies, Waldbronn, Germany).
LUHMES cells were differentiated on PLL/ﬁbronectin-
coated XFe96-well microplates (10,000 cells/well) and
infected with the AAV2-aSYN variants and EGFP as
respective controls for 72 h. Cells were brieﬂy washed
with growth medium, and the medium was replaced
before the measurements with 180 µl of assay medium
(containing 4.5 g/l glucose, 2 mM glutamine, 1 mM pyr-
uvate, pH 7.35). Cells with assay medium were incubated
at 37 °C for 60min. Three baseline measurements were
recorded before applying the different compounds. Oli-
gomycin was added in port A (20 µl) at a ﬁnal con-
centration of 3 µM, in port B 22.5 µl of FCCP
(carbonylcyanide-4-(triﬂuoromethoxy)-phenylhydrazone)
at a ﬁnal concentration of 0.4 µM and in port C 25 µl of
rotenone/antimycin A at a ﬁnal concentration of 1 µM.
Three measurements were performed after the addition of
each compound with 4min mixing intervals, followed by
3min measuring periods.
Active caspase staining
Caspase activation in LUHMES cells attributed to aSYN
toxicity was analysed by FITC-labelled FITC-VAD-FMK
in situ staining of active caspases. Following 72 h of AAV2
viral infection, cells were incubated with medium con-
taining 5 µM of FITC-VAD-FMK (G7461, Promega,
Madison, USA) for 30 min at 37 °C. Cells were brieﬂy
washed with PBS and imaged immediately with an epi-
ﬂuorescence microscope. Quantiﬁcation of active caspase
intensities was performed by using the Image J software
from at least three individual experiments.
Transmission electron microscopy
Mitochondrial ultrastructure of human dopaminergic
neurons was analysed by transmission electron micro-
scopy (TEM). Cells were cultured and differentiated on
micro sapphire plates coated with 0.1 mg/ml and 1 µg/ml
ﬁbronectin for AAV2 viral infections. Following 48 h of
viral infection, cells were cryo-immobilised on the sap-
phire plates by high-pressure freezing (HPF Compact 02,
Engineering Ofﬁce M. Wohlwend GmbH, Sennwald,
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Switzerland). Subsequently, the cells were freeze sub-
stituted with acetone in combination with 2% OsO4,
0.25% uranyl acetate, and 5% H2O
30–32. Freeze substitu-
tion was carried out in the automated AFS2 unit (Leica
Microsystems GmbH, Wetzlar, Germany) at −90 °C for
22 h, −60 °C for 8 h, −30 °C for 8 h, and then held at 0 °C
for 2 h. The heating time between each step was 1 h. After
washing the samples two times in ice-cold acetone, they
were gradually inﬁltrated in Epon 812 resin at room
temperature, followed by polymerisation at 60 °C for
3 days. Ultrathin sections of embedded samples were
collected on uncoated nickel grids (400 square mesh). For
immunolocalisation studies, cells were labelled with pri-
mary antibody against aSYN (Santa Cruz C20; Santa Cruz
Biotechnology, Dallas, USA) and secondary antibodies
were coupled to 20 nm gold particles. Labelling procedure
was performed as explained earlier32. Transmission elec-
tron micrographs were recorded with a JEOL TEM 2100
microscope operated at 120 kV equipped with a fast-scan
2 K × 2 K CCD camera F214 (TVIPS, Gauting, Germany).
Statistics
All data were calculated as means ± standard error of
the mean (SEM). Analysis of variance (ANOVA) was
performed followed by Scheffé’s post hoc test for statis-
tical comparisons between multiple groups. Calculations
were analysed using the WinStat standard statistical
software (R. Fitch Software, Bad Krozingen, Germany).
Statistical signiﬁcant differences were assumed at *p <
0.05, **p < 0.01, or ***p < 0.001.
Results
Disturbed ultrastructural integrity of mitochondria by
aSYN in differentiated LUHMES neurons
LUHMES neurons were differentiated to dopaminergic
phenotype as explained earlier20 and infected with the
AAV2 viruses for 3 days for the intended analysis
(experimental scheme Fig. 1a). AAV2-mediated expres-
sion of wild-type aSYN (aSYN) and mitochondria-
targeted aSYN (mito-aSYN) in LUHMES neurons were
ﬁrst analysed by Western blotting. LUHMES neurons
expressing WT-aSYN showed a band at 16 kDa repre-
senting the monomer of aSYN. We observed aSYN at
higher molecular weights corresponding to 55–60, 70 and
at 100–120 kDa despite denaturing conditions indicating
the formation of toxic aSYN oligomers (Fig. 1c). Inter-
estingly, neurons expressing mito-aSYN depicted two
bands corresponding to the monomer size and a 60 kDa
band representing the only oligomer observed (Fig. 1c).
Western blots showed that the formation of oligomers by
aSYN occurs predominantly in the cytoplasm and the
assembly patterns differ from the mito-aSYN.
We then tested the AAV2-mediated expression of WT-
aSYN and mito-aSYN or EGFP controls in the
dopaminergic neurons by immunocytochemistry and
ﬂuorescence imaging. To detect mitochondrial localisa-
tion of aSYN or EGFP, AAV2-transduced neurons were
stained with MitoTracker deep red before ﬂuorescence
imaging. Fluorescence microscopy of neurons infected
with AAV2-hSyn-mito-EGFP virus revealed that the
expression of EGFP was exclusively restricted to the
mitochondria (Fig. 1d, second panel). AAV2-hSyn-EGFP-
transduced neurons showed ubiquitous expression of
EGFP throughout the cell body including the neurites
(Fig. 1d, ﬁrst panel). Immunocytochemistry analysis of
aSYN in neurons transduced with AAV2-hSyn-mito-
aSYN identiﬁed co-localisation of aSYN with MitoTracker
red-stained mitochondria (Supplementary Fig. 1b, third
panel), while AAV2-hSyn-aSYN-mediated aSYN expres-
sion was detected throughout the cell body and the
neurites (Supplementary Fig. 1b, second panel). Non-
infected control cells show only endogenous aSYN
expression and did not co-localise in the mitochondria
(Supplementary Fig. 1b, ﬁrst panel). These results con-
ﬁrmed the functionality of AAV2 viruses and demon-
strated that both mitochondria-targeted aSYN and EGFP
constructs restricted their expression to the mitochondria
of dopaminergic neurons.
Investigations in post-mortem brain tissue identiﬁed the
mitochondrial presence of aSYN in the dopaminergic
neurons of PD patients4. The direct inﬂuence of aSYN on
mitochondrial structure and integrity in human dopami-
nergic neurons is unknown. With our new AAV system
for expression of MLS-tagged aSYN or WT-aSYN, we
investigated the effects of aSYN on the ultrastructural
integrity of mitochondria in human dopaminergic neu-
rons by electron microscopy. Control LUHMES neurons
or EGFP-expressing neurons showed intact mitochondria
with well-preserved double membranes and cristae
structures (Fig. 1e, Supplementary Fig. 1c). However,
neurons overexpressing WT-aSYN showed many frag-
mented mitochondria and depicted few or disorganised
cristae structures (Fig. 1e). However, neurons expressing
mito-aSYN displayed massively swollen mitochondria
with severely disturbed cristae structure (Fig. 1e, right
panel). In the cell bodies of mito-aSYN-expressing neu-
rons, the mitochondrial cristae structures were totally
disorganised and appeared as small vesicle-like structures
assembled at the periphery of the organelle (Fig. 1e, Box
1). These ﬁndings indicated pronounced structural
damage to the mitochondria by the mito-aSYN.
To validate whether the structural abnormalities could be
attributed to the mitochondrial localisation of aSYN, we
performed immunoelectron microscopy using immunogold
labelling of aSYN. In TEM analysis of the neurons expres-
sing WT-aSYN, we identiﬁed the presence of immunogold
particles in the cytoplasm (Supplementary Fig. 2a, Box 1), at
the nuclear membrane (Supplementary Fig. 2a, Box 2) and
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at the mitochondrial membrane (Supplementary Fig. 2b,
Box 3). Neurons expressing mitochondria-targeted aSYN
revealed exclusive localisation of immunogold particles in
the inner mitochondrial membrane conﬁrming accumula-
tion of mito-aSYN variant within the mitochondria (Sup-
plementary Fig. 2c, Box 4). These results demonstrate that
aSYN targets mitochondria and, when accumulating or
overexpressing mito-aSYN severely disturbs the structural
integrity of these organelles.
Mitochondrial dysfunction induced by aSYN in LUHMES
neurons
Considering the effect of aSYN on the structural
integrity of mitochondria, we explored the functional
consequences of WT and mito-aSYN overexpression in
the dopaminergic neurons. We conducted real-time
analysis of mitochondrial respiration function using the
Seahorse XFe96 analyser to measure oxygen consumption
rate (OCR). Neurons expressing either WT-aSYN or
mito-aSYN showed a severe decrease of the mitochondrial
basal respiration compared to EGFP controls (Fig. 2a). We
also observed a moderate decrease of the maximum
respiration in the controls expressing mito-EGFP (Fig. 2a).
However, effects of EGFP overexpression on mitochon-
drial parameters were always moderate and not as pro-
nounced as in cells overexpressing aSYN variants.
Further, aSYN variants expressing neurons showed a
signiﬁcant decline of ATP levels compared to naive or
EGFP controls (Fig. 2b). Notably, neurons expressing
mito-aSYN showed enhanced ATP level loss in compar-
ison to WT-aSYN-expressing neurons (Fig. 2b) implicat-
ing stronger toxicity of this mitochondria-targeted variant
as observed in the ultrastructural analysis. To show that
the differences detected in OCR (Fig. 2a) and cellular ATP
status (Fig. 2b) were speciﬁc consequences of aSYN
toxicity and not linked to increased cell mortality, we
determined the cell viability at different time intervals and
counted pyknotic nuclei in all the groups. We observed
signiﬁcant LDH release in the aSYN-expressing cells only
after 72 h and the remaining conditions at different time
points did not altered, indicating that the cells were in the
process of cell death (Supplementary Fig. 3a). Since
pyknotic nuclei are a hallmark of apoptosis, we observed
signiﬁcant increase in the number of pyknotic nuclei only
in the aSYN- and mito-aSYN-expressing neurons after
72 h of viral infection (Supplementary Fig. 3b). Therefore,
all the experiments performed in this study were after
72 h of viral infection.
It is established that ROS signiﬁcantly contribute to
mitochondrial damage and death signalling in neu-
rons29,33. This applies for aSYN toxicity, where an accu-
mulation of aSYN was linked to ROS formation mediating
the neurotoxic effects in model systems of PD34. Hence,
we examined the inﬂuence of aSYN on the generation of
mitochondrial ROS in the LUHMES neurons by staining
with the red ﬂuorescent MitoSOX dye. Neurons expres-
sing either WT or mito-aSYN showed a massive increase
in mitochondrial ROS compared to the EGFP controls
(Fig. 2c, e). These results indicated that aSYN over-
expression induced mitochondrial ROS formation in the
LUHMES neurons, and the mitochondrial localisation of
aSYN was sufﬁcient to induce such ROS formation in the
organelles. Next, we examined the mitochondrial mem-
brane potential by staining the LUHMES neurons with
the red ﬂuorescent TMRE dye. LUHMES neurons over-
expressing either form of aSYN displayed diminished
TMRE ﬂuorescence intensity compared to the EGFP
controls, indicating that aSYN induced a loss of the
mitochondrial membrane potential in the dopaminergic
neurons (Fig. 2d, f).
Enhanced cell death in LUHMES and primary cortical
neurons expressing mitochondria-targeted aSYN
We investigated the toxicity of the aSYN variants at the
level of neuronal network degeneration using β3-tubulin
immunostaining and MTT cell viability assay. LUHMES
(see ﬁgure on previous page)
Fig. 1 Altered mitochondrial structural integrity by aSYN expression in LUHMES neurons. a Schematic representation of the human
dopaminergic neuron differentiation and aSYN overexpression as a model system of PD. Days are numbered relative to the seeding (day −1),
differentiation (day 0), AAV viral infection (day 5) and analysis (day 8). b Cartoons depicting AAV2 viral vector genomes harbouring respective DNA
elements. TB, transcription blocker; hSynapsin, human synapsin promoter; EGFP, enhanced green ﬂuorescent protein; WPRE, woodchuck hepatitis
virus post-transcriptional regulatory element; pA, poly A transcription stop signal; MLS, mitochondrial localisation signal from cytochrome c;
aSynuclein, human wild-type aSYN; ITR, inverted terminal repeats. cWestern blot analysis of AAV2 viral-mediated EGFP, mitochondrial EGFP, aSYN and
mitochondrial aSYN in differentiated LUHMES cells. * indicates unspeciﬁc band present in all conditions. For convenience, Western blot image was
cut and rearranged in the order of treatment as depicted and the unaltered Western blot image was presented in the Supplementary Fig. 1a.
d Representative epiﬂuorescent images of differentiated LUHMES cells expressing cytosolic EGFP (ﬁrst panel) and mitochondrial EGFP (second panel)
following infection with AAV2-hSyn-EGFP and AAV2-hSyn-mito-EGFP. e Transmission electron microscopy (TEM) depicting well-preserved
mitochondrial cristae structures in differentiated human dopaminergic LUHMES neurons expressing EGFP controls. Neurons infected with WT-aSYN-
expressing AAV2 depicted many fragmented mitochondria marked by red arrows. Mitochondrial outer and inner cristae membranes were deformed
(M). Neurons expressing mitochondria-targeted aSYN identiﬁed many massively swollen mitochondria, and cristae structure was utterly deformed
and cornered to the periphery as small circular structures shown in inset (Box 1). (G, Golgi apparatus; M, mitochondria; N, nucleus)
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neurons expressing EGFP variants displayed a dense
neuronal network (Fig. 3a). In contrast, neurons expres-
sing mito-aSYN or WT-aSYN showed a severely degen-
erated neuronal network compared to the EGFP controls
(Fig. 3a). Quantiﬁcation of neuronal network conﬁrmed
signiﬁcant network degeneration in neurons expressing
WT-aSYN or mito-aSYN (Fig. 3b). Similarly, we observed
a signiﬁcant loss of cytoskeletal tubulin and actin protein
levels after transduction of either form of the aSYN as
veriﬁed by Western blotting (Fig. 1c). Cell viability assays
conﬁrmed that LUHMES or primary cortical neurons
expressing mitochondria-targeted or WT-aSYN under-
went signiﬁcant cell death compared to the EGFP controls
(Fig. 3c, d). These results conﬁrmed that the mito-aSYN
variant was more toxic to the neurons than the WT-
aSYN.
These ﬁndings demonstrate detrimental effects of aSYN
on the structural integrity and functional homeostasis of
Fig. 2 Expression of aSYN impairs mitochondrial function in LUHMES neurons. a Mitochondrial oxygen consumption rate (OCR) measurement
by Seahorse bioenergetics revealed expression of WT or mitochondrial aSYN mitigated mitochondrial respiration function of LUHMES cells, but not in
the EGFP controls. b LUHMES cell total ATP levels were measured following 72 h of AAV2 viral infection. Cells expressing WT and mitochondrial aSYN
showed signiﬁcant reduction in ATP levels compared to control (data are given as mean ± SEM; n= 3; ***p < 0.001 to control, #p < 0.05 to aSYN
ANOVA, Scheffe’s test. c, e Representative epiﬂuorescence microscopic images and quantiﬁcation of LUHMES cells stained with red ﬂuorescent
MitoSOX dye. Quantiﬁcation of MitoSOX-positive cells detected a signiﬁcant increase in mitochondrial ROS in cells expressing either WT-aSYN or
mitochondria-targeted aSYN compared to EGFP controls (data are given as mean ± SEM; n= 3; ***p < 0.001 to EGFP control, ANOVA, Scheffe’s test).
d, f Representative epiﬂuorescence microscopic images and quantiﬁcation of LUHMES cells stained with a red ﬂuorescent TMRE dye. Quantiﬁcation
of TMRE-positive cells identiﬁed severe loss of mitochondrial membrane potential in both WT and mitochondrial aSYN-expressing cells compared to
EGFP controls (data are given as mean ± SEM; n= 3; ***p < 0.001; **p < 0.01 to EGFP control, ANOVA, Scheffe’s test)
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mitochondria with according effects on bioenergetic
parameters in human dopaminergic neurons. Mitochon-
drial localisation of aSYN and according mitochondrial
disruption are sufﬁcient to mediate neurotoxicity. Thus,
identifying regulators connecting aSYN accumulation and
mitochondrial disintegration may provide effective stra-
tegies against aSYN neurotoxicity and PD pathology.
aSYN-induced cell death is mediated via caspase activation
in LUHMES neurons
To prevent the WT-aSYN-induced neurodegeneration,
we tested potential drug candidates based on our previous
observations (Supplement Table 1). We previously
demonstrated the neuroprotective role of HIF-PHD
inhibitor, DHB, in models of glutamate-induced oxida-
tive cell death35,36. The small conductance Ca2+-activated
K+ channels (SK channel) activator NS309 was previously
shown to prevent rotenone-induced oxidative cell death
in LUHMES neurons28. We tested the neuroprotective
ability of DHB and NS309 in LUHMES model system of
aSYN neurotoxicity. Neither of the compounds was able
to show signiﬁcant protective effect on aSYN-mediated
neurodegeneration in the LUHMES neurons (Fig. 4a, b).
Several observations suggest an involvement of caspases
in aSYN-mediated cell death37–39. We ﬁrst tested whether
activation of caspases occurs in WT-aSYN-expressing
LUHMES neurons using FITC-labelled zVAD-FMK
ﬂuorescence analysis. We observed a profound activation
of caspases upon aSYN expression as shown by FITC
staining’s and quantiﬁcation of ﬂuorescent intensities
(Fig. 4e, f). Then, we tested the neuroprotective role of
a broad caspase inhibitor QVD. LUHMES neurons
expressing WT-aSYN treated with QVD (10 µM) pro-
vided signiﬁcant protection against aSYN toxicity shown
by MTT assays (Fig. 4c). To conﬁrm the protective role of
caspase inhibition in this model, we applied another pan-
caspase inhibitor, zVAD-FMK (Fig. 4d). Again, the cyto-
toxicity of WT-aSYN in LUHMES neurons was abolished
by zVAD-FMK supporting the role of caspases in aSYN-
mediated cytotoxicity in LUHMES neurons.
Using broad range caspase inhibitors, we unveiled cas-
pases are involved in aSYN toxicity. However, which
Fig. 3 Enhanced neurotoxicity of mitochondria-targeted aSYN in LUHMES and primary rat cortical neurons. a, b Visualisation of neuronal
network degeneration by DAPI (blue) and β3-tubulin (red) immunostaining of differentiated human dopaminergic neurons expressing either WT or
mitochondria-targeted aSYN and EGFP control vectors. The degree of neuronal network degeneration is evident in aSYN variants expressing neurons
compared to EGFP controls. The degree of neuronal network disintegration was quantiﬁed using the Image J software and the intensity levels were
plotted (scale bar, 50 µm). (Data are given as mean ± SEM; n= 4; ***p < 0.001; **p < 0.01 to EGFP ANOVA–Scheffé’s test.) c, d MTT cell viability assays
conﬁrming both WT-aSYN and mitochondria-targeted aSYN induced signiﬁcant cell death in LUHMES and primary cortical neurons compared to
EGFP controls. Neurons expressing mitochondria-targeted aSYN depicted enhanced cell death compared to WT-aSYN. (Data are given as mean ±
SEM; n= 8; ***p < 0.001 to controls; ###p < 0.001; ##p < 0.01 to aSYN ANOVA–Scheffé’s test)
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Fig. 4 (See legend on next page.)
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speciﬁc caspase was involved in aSYN toxicity remained
to be resolved. We found that the caspase-1 inhibitor
(YVAD-CMK) prevented WT-aSYN-induced caspase
activation as shown by in situ staining and ﬂuorescent
intensity quantiﬁcations of active caspases (Fig. 4g, h).
Similarly, the caspase-1 inhibitor also enhanced the via-
bility of WT-aSYN-overexpressing dopaminergic neurons
as shown by MTT assay (Fig. 4i).
Pan-caspase inhibitor QVD rescues mitochondrial function
and electrical activity of LUHMES neurons overexpressing
aSYN
To further understand the role of caspase inhibition on
aSYN-induced LUHMES neuronal cell death, we deter-
mined the efﬁcacy of the pan-caspase inhibitor QVD on
mitochondrial respiration and network activity. There-
fore, we assessed the mitochondrial respiration by mea-
suring the OCR. Treatment with QVD alone did not alter
the basal mitochondrial respiration or maximal respira-
tion in comparison to the controls. Neurons expressing
WT-aSYN displayed a complete failure of mitochondrial
respiration function, and QVD signiﬁcantly ameliorated
the aSYN-induced bioenergetic failure (Fig. 5a). Further,
QVD rescued the ATP content in WT-aSYN-
overexpressing cells (Fig. 5b). TMRE staining and ﬂuor-
escence intensity quantiﬁcations revealed that QVD also
rescued the mitochondrial membrane potential despite
WT-aSYN overexpression (Fig. 5c, d).
Differentiated LUHMES dopaminergic neurons form an
active neuronal network and generate spontaneous action
potentials40. To determine the neuroprotective role of
QVD against aSYN toxicity at the functional level, we
analysed the electrical activity of LUHMES neurons using
patch-clamp technology. Voltage clamp recordings in the
on-cell conﬁguration revealed spontaneous action
potentials or synaptic inputs, with 69% of active cells in
controls, and 70% of active cells in QVD-treated controls
(Fig. 5e, f). Expression of aSYN drastically reduced the
neuronal activity and the number of active neurons to
25%. Treatment of aSYN-expressing neurons with QVD
signiﬁcantly doubled the number of electrically active cells
to 50% (Fig. 5e, f). These results suggest that inhibition of
caspase activation in aSYN neurotoxicity rescued not only
mitochondrial function but also restored electric activity
of the neuronal network.
Discussion
Our study demonstrates a particular role for mito-
chondrial damage in a model system of aSYN toxicity in
human dopaminergic LUHMES neurons. Using a
mitochondria-targeted aSYN construct, this study unveils
that mitochondrial localisation of aSYN is sufﬁcient to
induce severe ultrastructural deformation of the inner
mitochondrial cristae membranes, massive swelling and
complete loss of respiratory function. Both WT and mito-
aSYN overexpression induced a loss of mitochondrial
membrane potential and accumulation of mitochondrial
ROS. We demonstrate the involvement of caspases with a
particular contribution of caspase-1 in aSYN-mediated
neurodegeneration.
Several observations in brain tissues of PD patients and
transgenic animals expressing aSYN identiﬁed the pre-
sence of aSYN in the mitochondria4,17,41–43. The investi-
gation on differential co-expression identiﬁed a PD-
speciﬁc aSYN transcript with an extended 3′-UTR
(aSYN-L). Even though it is believed that aSYN is a
synaptic protein involved in neurotransmitter vesical
formation, mitochondrial localisation of aSYN-L is
attributed to a non-canonical mitochondrial localisation
signal19. However, direct pathological consequences of
mitochondrial aSYN have not been reported so far. Here,
we identiﬁed exacerbated neuronal toxicity by
mitochondria-targeted aSYN in human dopaminergic
cells and rodent cortical neurons, indicating the pertur-
bation of mitochondria by aSYN alone is critical for
neuronal viability. Concomitantly, both variants of aSYN
induced severe loss of the neuronal network, depletion of
cytoskeletal actin and tubulin levels and failure LUHMES
neuronal ﬁring. These observations are in line with recent
reports showing an interaction of aSYN with actin
(see ﬁgure on previous page)
Fig. 4 Inhibition of caspases prevented aSYN-induced LUHMES neuronal death, but not the iron chelator DHB or SK2 channel activator
NS309. a, b Inhibition of prolyl hydroxylases (PHD’s) by DHB 10 µM (ethyl-3,4-dihydroxybenzoate) or SK2 channel activator NS309 10 µM failed to
inhibit the LUHMES cell death-induced by WT-aSYN as analysed by MTT cell viability assays. (Data are given as mean ± SEM; n= 3; **p < 0.01 to
control, ANOVA, Scheffe’s test.). c, d MTT cell viability assays show inhibition of caspases with 10 µM of broad-spectrum caspase inhibitors QVD or
zVAD-FMK signiﬁcantly abolished WT-aSYN-induced LUHMES neuronal death. (Data are given as mean ± SEM; n= 4; ***p < 0.001 to control; ###p <
0.001, #p < 0.05 to aSYN, ANOVA, Scheffe’s test.) e, f Representative images and quantiﬁcation of green ﬂuorescent active caspases in aSYN-expressing
cells and treatment of 10 µM of QVD or zVAD-FMK prevented WT-aSYN-induced caspase activation. (Data are given as mean ± SEM; n= 3; ***p <
0.001 control, ##p < 0.01; $$p < 0.01 to aSYN, ANOVA, Scheffe’s test.) g, h Representative images and quantiﬁcation of green ﬂuorescent active caspases
in aSYN-expressing cells and treatment of 10 µM of caspase-1 inhibitor prevented WT-aSYN-induced caspase activation. (Data are given as mean ±
SEM; n= 3; ***p < 0.001 aSYN, ANOVA, Scheffe’s test.) i Cell viability assays showed inhibition of caspase-1 prevented WT-aSYN-induced LUHMES cell
death (Data are given as mean ± SEM; n= 3; ***p < 0.001 to control; ###p < 0.001 to aSYN, ANOVA, Scheffe’s test.)
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Fig. 5 Broad-spectrum caspase inhibitor QVD abolished aSYN-induced mitochondrial dysfunction and preserved electrophysiological
properties of LUHMES neurons. a Inhibition of caspases by 10 µM QVD protected mitochondrial oxygen consumption rate (OCR) in aSYN-
expressing LUHMES neurons (Data are given as mean ± SEM; n= 3; ***p < 0.001 to aSYN, ANOVA, Scheffé’s test). QVD alone did not show any impact
on mitochondrial respiration. b ATP analysis showed WT-aSYN-induced loss of ATP was preserved by 10 µM QVD treatment (Data are given as mean
± SEM; n= 3; ***p < 0.001 to control; ##p < 0.01 to aSYN, ANOVA, Scheffe’s test.) c, d Representative epiﬂuorescence microscopic images and
quantiﬁcation of ﬂuorescent intensities of TMRE in LUHMES cells stained with a red ﬂuorescent TMRE dye. QVD treatments show more number of
TMRE-positive cells compared to WT-aSYN. (Data are given as mean ± SEM; n= 3; **p < 0.01 to control; ##p < 0.01 to aSYN, ANOVA, Scheffe’s test.)
e Recordings of action potentials obtained in the on-cell conﬁguration and f the number of active cells per condition are illustrated. WT-aSYN-
induced loss of spontaneous membrane potentials was prevented by QVD treatment. The numbers on top of each bar denote the number of cells
used for measurement
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resulted in impaired cytoskeletal dynamics and neuronal
network degeneration44.
Oxidative stress is a signiﬁcant contributor of neuro-
degeneration in models relevant to synucleinopathies and
PD. Increased ROS environment promotes cell organelle
dysfunction and post-translational modiﬁcations of aSYN,
such as phosphorylation of serine 129, nitration and
ubiquitination, thereby facilitating the formation of toxic
oligomers45–48. Accordingly, LUHMES neurons expres-
sing WT-aSYN generated high molecular weight aggre-
gates ranging from 50 to 120 kDa of aSYN resistant to
denaturing conditions. Interestingly, neurons expressing
mito-aSYN did not show prominent high molecular
weight aggregates even though mitochondria are one
major source of ROS, and this is often further increased in
damaged mitochondria. These ﬁndings imply that the
molecular events contributing to aSYN aggregation
mainly occur outside the mitochondria.
Mitochondria are highly dynamic organelles undergoing
dynamic ﬁssion–fusion processes in a regulated manner.
In conditions of oxidative stress, increased mitochondrial
ﬁssion contributes to mitochondrial damage and failure of
cellular energy metabolism49. A role for mitochondrial
dysfunction in the pathogenesis of PD has long been
appreciated. Studies demonstrating mitochondrial accu-
mulation of aSYN in PD brain tissue proposed that aSYN
may regulate mitochondrial homeostasis and morphol-
ogy4,18,50,51. Therefore, the role of aSYN on mitochondrial
ultrastructural and functional dynamics was further elu-
cidated in the present model of aSYN neurotoxicity in
LUHEMS neurons. TEM analysis of dopaminergic neu-
rons overexpressing WT-aSYN revealed many frag-
mented mitochondria displaying less and malformed
cristae in the mitochondria.
Even though aSYN constitutes 1% of the total protein
present in neurons and lacks a canonical mitochondrial
localisation signal, previous studies proposed essential
mechanisms contributing to mitochondrial translocation of
aSYN41–43,52,53. Electron paramagnetic resonance spectro-
scopy studies revealed that aSYN interacts explicitly with
cardiolipin containing inner mitochondrial membranes54.
However, the impact of mitochondrial aSYN translocation
remained unclear. Using a mito-aSYN construct, we exposed
complete distortion of inner cristae structure and swelling of
the mitochondria. Intriguingly, the mitochondrial inner
cristae membranes were reorganised into small circular
structures and were padded at the perimeter of the enlarged
mitochondria of the dopaminergic neurons. These circular
structures may resemble synaptic vesicles present at the
nerve terminals. Due to the amphipathic nature of the N-
terminal of the protein, aSYN adopts an extended amphi-
pathic alpha-helix conformation upon binding with lipid
bilayers. Thereby, aSYN can remodel the lipid bilayer to a
rounded membrane resulting in highly curved, vesicle-like
structures55,56. In this context, our TEM observations in
mitochondria-targeted aSYN-expressing neurons provide
direct evidence of membrane remodelling by aSYN in the
targeted mitochondria.
The human brain is a highly energy-consuming organ,
and, therefore, mitochondrial dysfunction and impaired
energy metabolism are major hallmarks of neurodegen-
erative diseases. Studies in PD patient’s brains suggested
that accumulation of aSYN in the mitochondria impaired
the function of the mitochondrial complex I4. We found a
failure of mitochondrial bioenergetics in LUHMES neu-
rons overexpressing mito-aSYN or WT-aSYN. Conse-
quently, aSYN expression signiﬁcantly decreased the
cellular ATP levels indicating a direct impact of aSYN
modulation on the cellular energy status. The data pre-
sented for mitochondrial respiration (OCR) and ATP
measurements represent endpoint data, reﬂecting the
remaining mitochondrial function and overall ATP pro-
duction in the surviving cells. The effects of aSYN may
thus be over-estimated, because fewer cells contribute to
these endpoints (Supplementary Fig 3a). However, the
bioenergetic indices, like ATP production calculated from
basal respiration levels, the different respiratory states and
maximal respiration over basal respiration are relative
values, which also conﬁrm reduced mitochondrial func-
tion in the surviving cells exposed to aSYN. Notably, in
cells treated with caspase inhibitors, ATP levels were
rescued (Fig. 5b), whereas mitochondrial dysfunction was
only partly attenuated (Fig. 5a), suggesting that mito-
chondrial respiration partly contributed to the energy
supply in the protected cells. In models of oxidative
stress-induced cell death, we previously documented that
mitochondrial dysfunction was associated with increased
mitochondrial ROS formation and loss of mitochondrial
membrane potential49. Similarly, aSYN-induced mito-
chondrial dysfunction enhanced mitochondrial ROS
levels and disruption of the mitochondrial membrane
potential leading to dopaminergic neurodegeneration.
In neurodegenerative diseases, the underlying pro-
gressive neuronal cell death is considered as a highly
regulated process. Reduced glutathione levels, enhanced
lipid peroxidation and mitochondrial demise promote an
increased pool of labile iron in the cytosol contributing in
iron-dependent non-apoptotic PCD coined as ferroptosis.
Our observations showed that removal of intracellular
labile iron with iron-chelators like DHB ameliorated
errastin-induced ferroptotic cell death49. In light of these
and other observations10, we tested the neuroprotective
efﬁcacy of the iron chelator DHB in our WT-aSYN model
of PD. In contrast to earlier observations in ferroptosis,
DHB failed to prevent aSYN toxicity in LUHMES neu-
rons. Similarly, in rotenone-induced oxidative stress
model, SK channel activation by NS309 provided neuro-
protection in LUHMES cells28. However, NS309 did not
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prevent the WT-aSYN-induced LUHMES neurodegen-
eration, suggesting that the pathways involved in complex
I targeting toxin-mediated cell death may differ in dopa-
minergic neurons.
Loss of mitochondrial integrity is considered as a point
of no return in paradigms of cell death. Compromised
mitochondria release cytochrome c into the cytoplasm,
thereby inducing the activation of caspases. In mammals,
ten caspases are classiﬁed based on their primary role,
such as initiator caspase-2, -8, -9, and -10, or executioner
caspase-3, -6 and -7, and caspase-1, -4 (in humans) and -5
are associated with inﬂammatory responses57. Caspases
are also involved in cell proliferation, cellular remodelling
cell fate determination and immune responses58. Studies
in PD patient brains and animal models of PD presented a
positive correlation of activated caspase-1, -3, -8 and -9 in
dying dopaminergic neurons59–61. Moreover, studies in
hippocampal neuronal cells (HT22) demonstrated that
extracellular aSYN induces caspase-3 activation and
apoptosis13. Here, we found signiﬁcant caspase activation
in WT-aSYN-expressing dopaminergic LUHMES neu-
rons. Inhibition of caspases with the pan-caspase inhibi-
tors QVD or zVAD-FMK signiﬁcantly ameliorated aSYN
toxicity. Notably, caspase inhibition improved not only
mitochondrial respiratory function and rescued cellular
ATP levels but also enhanced electrophysiological prop-
erties of aSYN-expressing neurons. Similarly, Vekrellis
et al.38 reported that inhibition of caspases abrogated
aSYN-induced mitochondrial cytochrome c release and
caspase-mediated SHSY-5Y neuroblastoma cells death.
Collectively, these results implicate the possible invol-
vement of caspases in aSYN toxicity upstream of mito-
chondrial damage such as caspase-1, -2 or -862. In fact, we
found that inhibition of caspase-1 ameliorated aSYN-
induced neurodegeneration. Caspase-1 is known as
NLRP3 inﬂammasome-activating or interleukin-
converting enzyme and is regarded as a key mediator of
inﬂammatory process. In addition, caspase-1-mediated cell
death is known as pyroptosis in macrophages following
infection. Furthermore, caspase-1 was shown to induce
apoptosis involving Bid (BH3-interacting domain) and
mitochondrial-dependent activation of caspase-3 in stroke
models63. Recent ﬁndings reveal that involvement of
caspase-1 activated NLRP3 inﬂammasome via mitochon-
drial ROS production induced profound neurodegenera-
tion in MPTP-treated microglia-neuron co-culture
model64. Concomitantly, inhibition of caspases was effec-
tive in preventing the aSYN toxicity despite the marked
impairment of mitochondrial structure, implying
unknown caspase-dependent mechanisms upstream of
mitochondrial pathways of aSYN toxicity. Even though the
mode of cell death observed is caspase-dependent, we did
not detect typical apoptotic nuclear morphology in TEM
suggesting an involvement of a tapestry of mechanisms in
aSYN-induced dopaminergic neurodegeneration.
Altogether, we unveiled the fatal remodelling of mito-
chondrial cristae membranes by aSYN leading to an
extensive swelling and bioenergetic failure of the mito-
chondria in human dopaminergic neurons. We demon-
strated that caspase inhibition reversed aSYN-induced
mitochondrial dysfunction and neuronal death, suggest-
ing that caspase inhibition and speciﬁcally inhibition of
caspase-1 might be an effective therapeutic strategy in
synucleinopathies including PD.
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